Establishment Labs Holdings Inc (ESTA) Q1 2026 Earnings Call Transcript

Why It Matters

The shift to profitability and higher margins validates Establishment Labs’ commercial strategy, positioning it to capture a larger share of the fast‑growing breast‑augmentation market and fund upcoming product launches without dilutive financing.

Key Takeaways

• Revenue up 33.7% YoY to $53.8M
• Gross margin exceeds 70% for first time
• Adjusted EBITDA positive $1.2M
• Over 1,300 U.S. surgeons using Motiva
• 300 PRESIVE cases; 100‑woman waitlist

Pulse Analysis

Establishment Labs’ Q1 2026 results signal a turning point for the medical‑device maker, as revenue surged past the $50 million mark and gross margins cracked the 70% barrier. The margin expansion stems largely from higher‑margin U.S. implant sales and disciplined expense management, which together delivered the first quarter of positive adjusted EBITDA. This financial inflection reduces reliance on equity raises and gives the company a stronger runway to invest in growth initiatives, including its minimally invasive PRESIVE platform.

In the United States, the company’s Motiva silicone‑gel implants are gaining rapid acceptance, now featured in the practices of more than 1,300 surgeons. The brand’s premium positioning, combined with strong patient demand for safety and aesthetic outcomes, is driving a 16% sequential revenue lift even in a traditionally slow Q3 period. Early adoption of PRESIVE, with roughly 300 procedures performed and a growing waitlist, underscores the market’s appetite for less invasive, higher‑priced solutions, supporting the firm’s goal of a 20% U.S. market share by year‑end.

Beyond North America, direct‑to‑market operations delivered 15% year‑over‑year growth, while Asia‑Pacific orders rebounded 46% sequentially. A bolstered cash balance of $70.6 million—augmented by a $25 million credit facility draw—provides liquidity for upcoming product approvals, notably the U.S. breast‑reconstruction launch slated for early 2026. Management’s raised 2025 revenue outlook above $210 million and the projection of a $30 million minimally invasive portfolio in 2026 highlight a clear growth trajectory anchored by product innovation and expanding global distribution.